Review article: Advancements in Targeted Molecular Therapy for Human Papillomavirus (HPV) Related Cancer
Amanda Szymanski, Joel E. Mortensen, Patricia Tille
Cetuximab and gefitinib are two recently developed molecular targeted therapy drugs that target epidermal growth factor receptors (EGFR) to deactivate molecular pathways responsible for cancer growth. Both drugs are proven to be safe and effective therapy options that can improve the patient’s overall survival and decrease disease recurrence. However, drug resistance remains problematic for patients using molecular targeted therapy. A common solution is combining molecular targeted therapy with additional options such as chemotherapy or other targeted therapies. This has the potential to eliminate drug resistance. However, there are limited target therapies available for HPV cancer. This demonstrates the need for further research and drug development for HPV related cancer cases to make further advancements.
Key words: Human papilloma virus; Cancer; Molecular targeted therapy; Molecular target identification; Oropharyngeal; Molecular detection; miRNAs; Epidermal growth factor signaling; Kinase inhibitors; Monoclonal antibodies; Cetuximab; Gefitinib; Resistance; T790M
Int. J. Bio. Lab. Sci 2022(11)2:71-79 【PDF】